Elsevier

Biochemical Pharmacology

Volume 73, Issue 8, 15 April 2007, Pages 1195-1204
Biochemical Pharmacology

Molecular aspects of the histamine H3 receptor

https://doi.org/10.1016/j.bcp.2007.01.008Get rights and content

Abstract

The cloning of the histamine H3 receptor (H3R) cDNA in 1999 by Lovenberg et al. [10] allowed detailed studies of its molecular aspects and indicated that the H3R can activate several signal transduction pathways including Gi/o-dependent inhibition of adenylyl cyclase, activation of phospholipase A2, Akt and the mitogen activated kinase as well as the inhibition of the Na+/H+ exchanger and inhibition of K+-induced Ca2+ mobilization. Moreover, cloning of the H3R has led to the discovery several H3R isoforms generated through alternative splicing of the H3R mRNA.

The H3R has gained the interest of many pharmaceutical companies as a potential drug target for the treatment of various important disorders like obesity, myocardial ischemia, migraine, inflammatory diseases and several CNS disorders like Alzheimer's disease, attention-deficit hyperactivity disorder and schizophrenia.

In this paper, we review various molecular aspects of the hH3R including its signal transduction, dimerization and the occurrence of different H3R isoforms.

Introduction

In the historical context of histamine's pharmacology our current knowledge on the third histamine receptor has been gathered in a very short period of time. After the discovery of histamine's biological actions in 1910 [1], the first two histamine receptors were proposed in 1966 [2] and 1972 [3], based on classical pharmacological rules of drug selectivity. Using a similar strategy it was ultimately the French research group at INSERM, led by Jean-Michel Arrang and Jean-Charles Schwartz [4], which described in 1983 for the first time an additional histamine receptor, mediating a negative feedback on the release of histamine from rat brain slices.

With the rapid expansion in the knowledge on the molecular aspects of the histamine H3 receptor (H3R) following cloning of the receptor cDNA, it has been recognized as a promising G-protein coupled receptor (GPCR) target in the CNS for the treatment of a variety of diseases, e.g. obesity and cognitive disorders (for detailed reviews see [5], [6], [7], [8], [9]). Moreover, at present we are overwhelmed with a large increase in our knowledge on the molecular aspects of H3R. Especially in the last decade important new data have been generated, following the seminal paper of the Johnson & Johnson team lead by Tim Lovenberg on the cloning of the human H3R (hH3R) [10]. Despite the fact that both the histamine H1 and H2 receptor cDNA's sequences were known since the early nineties [11], [12] and substantial efforts of various laboratories to clone the H3R cDNA on the basis of homology with the other two histamine receptors, it lasted until 1999 to elucidate the molecular architecture of the hH3R [10]. Following a large scale effort to clone CNS-expressed (orphan) GPCRs, Lovenberg et al. [10] identified and subsequently ‘deorphanised’ the hH3R. The isolated hH3R cDNA encoded a 445 amino acid protein with all the hallmarks of the family A, rhodopsin-like GPCR [13], and finally confirmed initial suggestions of the GPCR nature of the H3R based on H3R agonist-induced [35S]GTPγS binding [14], [15], GTP- and PTX-sensitivity of H3R radioligand binding and/or responses [14], [16], [17].

With the identification of the hH3R cDNA, histamine receptor research was boosted a great deal and enormous progress has been made in the field ever since. The new information resulted in the identification of a novel histamine receptor, H4[18], and also evoked strong interest of many pharmaceutical companies to develop H4R selective ligands [6], [8]. Whereas the H3R has been considered by many companies as an interesting target even before 1999, the lack of molecular information and thus the availability of recombinant systems, made most companies hesitant to start drug discovery programs. A recent review by Hancock [19] on the large drug discovery efforts by Abbott Laboratories, nicely illustrates how the lack of the hH3R as a screening tool resulted in an initial setback in Abbott's H3R program. Nevertheless, their early entry in the H3R field ensured Abbott a strong position in the present H3R field [8], [19]. With the present availability of the H3R cDNA many major pharmaceutical companies have joined the search for selective and potent H3R antagonists [8]. The development of H3R ligands has recently been elaborately documented in various reviews [5], [8], [19], [20], [21].

The cloning of the H3R cDNA has also led to a detailed delineation of several molecular aspects of H3R pharmacology. With the identification of the chromosomal localization and the elucidation of the genomic H3R sequence, it became clear that the H3R gene contains various introns and, thus, alternative splicing might result in various H3R isoforms. Indeed, soon after the cloning of the hH3R cDNA, at least 20 human [22], [23], [24], [25], [26], [27], [28] and several rodent [29], [30] isoforms have been identified. In this review we present an overview of the H3R isoforms and their known signal transduction pathways for a better understanding of the mechanism of action of H3R antagonists as potential therapeutics (Fig. 1).

Section snippets

Genomic organization of the H3R

The hH3R gene is located on chromosome 20 at location 20q13.33 (HRH3 GeneID: 11255) and the coding region has been suggested to consist of either three exons and two introns (GenBank accession number AL078633) [31], or four exons and three introns [22]. Alternatively, the most 3′ intron has been proposed to be a pseudo-intron as it is retained in the hH3R(445) isoform, but deleted in the hH3R(413) isoform [23]. In the coding region for the hH3R(445) exon 1 codes for transmembrane domain (TM) 1

Identification of H3R isoforms

To date at least 20 isoforms of the hH3R are known and in addition several H3R isoforms have been identified in rat, guinea-pig and mouse as well [22], [23], [24], [28], [29], [30], [31], [37], [40], [41]. So far no isoforms were found for the monkey H3R [39]. The complete spectrum of H3R isoforms might be highly species-specific, complicating the evaluation of the various isoforms in relation to the effectiveness of H3R ligands in vivo.

For the hH3R, alternative splicing occurs in four

Inhibition of adenylyl cyclase

Early experiments studying the receptor function employing pertussis toxin (PTX) using various assay systems, such as AtT-20 cells endogenously expressing the H3R [17], the guinea pig atria [42] and modulation of the H3R induced [35S]-GTPγS binding in rat brain [43], suggested that the H3R might be Gαi/o-coupled [14]. Expression of the cloned H3R cDNA in SK-N-MC cells confirmed the linkage of the hH3R to Gαi/o-proteins by showing its ability to inhibit the forskolin induced cAMP formation in a

Expression of the H3R isoforms

The initial cloning of the hH3R gene demonstrated that the full length receptor is a hH3R(445) amino acid G-protein coupled receptor that is found almost exclusively in the brain [10]. Whether the so far described isoforms indeed play an important role will depend on their expression levels and potential differential expression. Cogé et al. [22] showed by Northern blots analysis a high signal for the hH3R(445) in thalamus, caudate nucleus, putamen and cerebellum, a lower signal in the amygdala

Pharmacological characteristics of H3R isoforms

Pharmacological characterization of different hH3R isoforms have been described in two publications (Table 1). Of the six isoforms cloned by Cogé et al. [22], three isoforms (hH3R(445), hH3R(431), hH3R(365)) were expressed in CHO cells and pharmacologically characterized, with a focus on the hH3R(445) and hH3R(365). The hH3R(431), which lacks 14 amino acids at the C-terminal end of TM2, showed no [125I]Iodoproxyfan radioligand binding. Whereas this deletion does not affect the key-residues in

Dimerization of H3Rs

The concept of GPCR dimerization is now well documented in literature (for detailed reviews see [98]), and such direct protein–protein interactions between different GPCRs are suggested to allow a whole vista of possibilities for subtle changes in the pharmacology of these GPCRs from their monomeric, homo-dimeric or -oligomeric entities, which were previously attributed to the existence of additional receptor subtypes. In view of the recent discovery of H3R isoforms, which are often

Concluding remarks

The cloning of the hH3R has led to the discovery of several signal transduction pathways that are modulated by the hH3R. Some of these signaling pathways can be linked to relevant pathophysiologies. The hH3R-mediated inhibition of the NHE leads to a subsequent lowering in the exocytosis of norepinephrine and thereby providing an explanation for the protective role of hH3R agonists during myocardial ischemia. The cloning of the receptor gene resulted in the elucidation of the genomic

References (100)

  • J. Chen et al.

    Molecular and pharmacological characterization of the mouse histamine H3 receptor

    Eur J Pharmacol

    (2003)
  • B.B. Yao et al.

    Cloning and pharmacological characterization of the monkey histamine H3 receptor

    Eur J Pharmacol

    (2003)
  • E. Sanchez-Lemus et al.

    Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices

    Neurosci Lett

    (2004)
  • E.P. Brandon et al.

    PKA isoforms, neural pathways, and behaviour: making the connection

    Curr Opin Neurobiol

    (1997)
  • E. Poli et al.

    Histamine H3-receptor-induced inhibition of duodenal cholinergic transmission is independent of intracellular cyclic AMP and GMP

    Gen Pharmacol

    (1993)
  • R.A. Bond et al.

    Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery

    Trends Pharmacol Sci

    (2006)
  • T. Costa et al.

    Historical review: Negative efficacy and the constitutive activity of G-protein-coupled receptors

    Trends Pharmacol Sci

    (2005)
  • T. Kenakin

    Pharmacological proteus?

    Trends Pharmacol Sci

    (1995)
  • C. Murga et al.

    Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinasegamma

    J Biol Chem

    (1998)
  • D.P. Brazil et al.

    Advances in protein kinase B signalling: AKTion on multiple fronts

    Trends Biochem Sci

    (2004)
  • K. Karlstedt et al.

    Expression of the H3 receptor in the developing CNS and brown fat suggests novel roles for histamine

    Mol Cell Neurosci

    (2003)
  • J. Segarra et al.

    Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for met-triggered cortical neuron migration

    J Biol Chem

    (2006)
  • N. Adachi et al.

    Aggravation of ischemic neuronal damage in the rat hippocampus by impairment of histaminergic neurotransmission

    Brain Res

    (1993)
  • A. Lozada et al.

    Postischemic regulation of central histamine receptors

    Neuroscience

    (2005)
  • M. Lintunen et al.

    Transient changes in the limbic histaminergic system after systemic kainic acid-induced seizures

    Neurobiol Dis

    (2005)
  • W. Siffert et al.

    Sodium fluoride prevents receptor- and protein kinase C-mediated activation of the human platelet Na+/H+ exchanger without inhibiting its basic pHi-regulating activity

    J Biol Chem

    (1990)
  • I. Visiers et al.

    Three-dimensional representations of G protein-coupled receptor structures and mechanisms

    Methods Enzymol

    (2002)
  • K. Kristiansen

    Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function

    Pharmacol Therap

    (2004)
  • E. Rands et al.

    Mutational analysis of beta-adrenergic receptor glycosylation

    J Biol Chem

    (1990)
  • H.H. Dale et al.

    The physiological action of β-imidazolethylamine

    J Physiol

    (1910)
  • A.S. Ash et al.

    Receptors mediating some actions of histamine

    Br J Pharmacol Chemother

    (1966)
  • J.W. Black et al.

    Definition and antagonism of histamine H2-receptors

    Nature

    (1972)
  • J.M. Arrang et al.

    Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor

    Nature

    (1983)
  • T.A. Esbenshade et al.

    Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders

    Mol Intervent.

    (2006)
  • R. Leurs et al.

    The histamine H3 receptor: from gene cloning to H3 receptor drugs

    Nat Rev

    (2005)
  • A.A. Hancock et al.

    Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists

    Expert Opin Invest Drugs

    (2005)
  • A.A. Hancock et al.

    Perspectives on cognitive domains, H3 receptor ligands and neurological disease

    Expert Opin Invest Drugs

    (2004)
  • T.W. Lovenberg et al.

    Cloning and functional expression of the human histamine H3 receptor

    Mol Pharmacol

    (1999)
  • M. Yamashita et al.

    Expression cloning of a cDNA encoding the bovine histamine H1 receptor

    Proc Natl Acad Sci USA

    (1991)
  • I. Gantz et al.

    Molecular cloning of a gene encoding the histamine H2 receptor

    Proc Natl Acad Sci USA

    (1991)
  • J.T. Laitinen et al.

    Guanosine 5′-(gamma-[35S]thio)triphosphate autoradiography allows selective detection of histamine H3 receptor-dependent G protein activation in rat brain tissue sections

    J Neurochem

    (1998)
  • F.P. Jansen et al.

    Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain

    Br J Pharmacol

    (1994)
  • M.A. Clark et al.

    Guanine nucleotides and pertussis toxin reduce the affinity of histamine H3 receptors on AtT-20 cells

    Agents Actions

    (1993)
  • M. Cowart et al.

    Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists

    Mini Rev Med Chem

    (2004)
  • H. Stark et al.

    Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists

    Mini Rev Med Chem

    (2004)
  • F. Cogé et al.

    Genomic organization and characterization of splice variants of the human histamine H3 receptor

    Biochem J

    (2001)
  • J. Tardivel-Lacombe et al.

    Chromosomal mapping and organization of the human histamine H3 receptor gene

    Neuroreport

    (2001)
  • Tsui P. Human histamine H3 gene variant-2. WO/2001/068703,...
  • Tsui P. Human histamine H3 gene variant-3. WO/2001/068816,...
  • Gallagher M, Yates SL. Histamine H3 receptor polynucleotides. WO/2003/042359,...
  • Cited by (108)

    View all citing articles on Scopus
    1

    Current address: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

    View full text